Risultati della ricerca - Oaknin, Ana

Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? di Lorusso, Domenica, Ray-Coquard, Isabelle, Oaknin, Ana, Banerjee, Susana

Testo Testo Testo

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 di Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.

Testo Testo Testo

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways di Birrer, Michael J., Fujiwara, Keiichi, Oaknin, Ana, Randall, Leslie, Ojalvo, Laureen S., Valencia, Christian, Ray-Coquard, Isabelle

Testo Testo Testo

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion di Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle

Testo Testo Testo

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab di Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.

Testo Testo Testo

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer di Rodriguez-Freixinos, Victor, Ruiz-Pace, Fiorella, Fariñas-Madrid, Lorena, Garrido-Castro, Ana Christina, Villacampa, Guillermo, Nuciforo, Paolo, Vivancos, Ana, Dienstmann, Rodrigo, Oaknin, Ana

Testo Testo Testo

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors di Poveda, Andres, Oaknin, Ana, Romero, Ignacio, Guerrero-Zotano, Angel, Fariñas-Madrid, Lorena, Rodriguez-Freixinos, Victor, Mallol, Pedro, Lopez-Reig, Raquel, Lopez-Guerrero, Jose Antonio

Testo Testo Testo

Management of advanced ovarian cancer in Spain: an expert Delphi consensus di Redondo, Andres, Oaknin, Ana, Rubio, Maria Jesus, Barretina-Ginesta, Maria-Pilar, de Juan, Ana, Manso, Luis, Romero, Ignacio, Martin-Lorente, Cristina, Poveda, Andres, Gonzalez-Martin, Antonio

Testo Testo Testo

Improved Survival with Bevacizumab in Advanced Cervical Cancer di Tewari, Krishnansu S., Sill, Michael W., Long, Harry J., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.

Testo Testo Testo

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A... di Oaknin, Ana, Tinker, Anna V., Gilbert, Lucy, Samouëlian, Vanessa, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, Sabatier, Renaud

Testo Testo Testo

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study di Poveda, Andres, Lopez-Reig, Raquel, Oaknin, Ana, Redondo, Andres, Rubio, Maria Jesus, Guerra, Eva, Fariñas-Madrid, Lorena, Gallego, Alejandro, Rodriguez-Freixinos, Victor, Fernandez-Serra, Antonio, Juan, Oscar, Romero, Ignacio, Lopez-Guerrero, Jose A.

Testo Testo Testo

Patient Reported Outcomes in a Practice Changing Randomized Trial of Bevacizumab in the Treatment of Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study di Penson, Richard T., Huang, Helen Q., Wenzel, Lari B., Monk, Bradley J., Stockman, Sharon, Long, Harry J., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J.A., Leitao, Mario M., Method, Michael, Michael, Helen, Tewari, Krishnansu S.

Testo Testo Testo

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer di Makker, Vicky, Taylor, Matthew H., Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., DiSimone, Christopher, Messing, Mark, Stepan, Daniel E., Dutcus, Corina E., Wu, Jane, Schmidt, Emmett V., Orlowski, Robert, Sachdev, Pallavi, Shumaker, Robert, Casado Herraez, Antonio

Testo Testo Testo

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial di Naumann, R. Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M., Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R.J., Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L., Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N.

Testo Testo Testo

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial di DiSilvestro, Paul, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S., Gourley, Charlie, Banerjee, Susana, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol A., Bradley, William H., Mathews, Cara A., Liu, Joyce, Lowe, Elizabeth S., Bloomfield, Ralph, Moore, Kathleen N.

Testo Testo Testo

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade di Romero, Octavio A., Vilarrubi, Andrea, Alburquerque-Bejar, Juan J., Gomez, Antonio, Andrades, Alvaro, Trastulli, Deborah, Pros, Eva, Setien, Fernando, Verdura, Sara, Farré, Lourdes, Martín-Tejera, Juan F., Llabata, Paula, Oaknin, Ana, Saigi, Maria, Piulats, Josep M., Matias-Guiu, Xavier, Medina, Pedro P., Vidal, August, Villanueva, Alberto, Sanchez-Cespedes, Montse

Testo Testo Testo

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... di Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

Testo Testo Testo

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib di Kwan, Tanya T., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin, Ana, Aghajanian, Carol, Lorusso, Domenica, Colombo, Nicoletta, Dean, Andrew, Weberpals, Johanne, Severson, Eric, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Harding, Thomas, Kaufmann, Scott H., Ledermann, Jonathan A., Coleman, Robert L., McNeish, Iain A., Lin, Kevin K., Swisher, Elizabeth M.

Testo Testo Testo

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells di Muñoz-Guardiola, Pau, Casas, Josefina, Megías-Roda, Elisabet, Solé, Sònia, Perez-Montoyo, Héctor, Yeste-Velasco, Marc, Erazo, Tatiana, Diéguez-Martínez, Nora, Espinosa-Gil, Sergio, Muñoz-Pinedo, Cristina, Yoldi, Guillermo, Abad, Jose L, Segura, Miguel F, Moran, Teresa, Romeo, Margarita, Bosch-Barrera, Joaquim, Oaknin, Ana, Alfón, Jose, Domènech, Carles, Fabriàs, Gemma, Velasco, Guillermo, Lizcano, Jose M

Testo Testo Testo

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as mainten... di Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S

Testo Testo Testo